BioSpace News Archive

Edesa Biotech’s EBO1, a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), showed mixed results compared to placebo in Phase II, the company announced Tuesday.

Freelance workers are a significant component of the biopharma industry. Join us as we take a look at a few biopharma freelancing opportunities and learn where to find them.

Shockwave Medical bolsters medical device portfolio with acquisition of Neovasc.

Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc.

TC BioPharm and MD Anderson signed a three-year collaboration to better understand the role of gamma delta T cells in cancer treatment.

Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company.

Duke University’s BIG IDEAs Lab and Evidation, the company that connects directly with individuals to measure and improve health in everyday life, announced today that they have established a partnership with the goal of increasing diversity and representation in digital health studies.

VySpine announced today that it has received 510(k) clearance from the FDA for its LumiVy NanoVy Ti Lumbar IBF System which is indicated for intervertebral body fusion for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis.

Cycle Pharmaceuticals Ltd (Cycle) has today welcomed the news that multiple sclerosis (MS) patients in the US currently being treated with Gilenya, or generic fingolimod to have access to appropriate patient support services alongside the bioequivalent, TASCENSO ODT1 following the withdrawal of Gilenya patient support on March 31st 2023.

Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”) today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the the B. Riley Securities 3rd Annual Oncology Conference, to be held virtually from January 18-19, 2023.